7 May 2009 - Cellcentric has expanded its agreement with Shanghai-based HD Biosciences (HDB) to move epigenetic targets from screening into drug discovery.
Prior to signing the master services agreement, Cellcentric and HDB worked together on an initial set of targets identified and prioritised by Cellcentric.
The new agreement provides a framework to drive these programmes forward. 21 April 2009 - Cellcentric has reinforced its discovery base by securing an agreement covering Prof Ramin Shiekhattar and Prof Luciano Di Croce at the Center for Genomic Regulation, Barcelona. The company, a biotechnology group unlocking epigenetic control mechanisms, now has ties with 25 laboratories across the world.
